POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
https://technainstitute.com/wp-content/uploads/2021/01/Screen-Shot-2021-01-12-at-9.27.14-AM.png 619 255 Techna Techna https://technainstitute.com/wp-content/uploads/2021/01/Screen-Shot-2021-01-12-at-9.27.14-AM.pngPOINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment TORONTO, Jan. 12, 2021…
read more